-
Typical symtpoms of GERD
- belching
- globulous sensation
- heartburn
- regurgitation
- sour stomach
- water brash
-
Atypical symptoms of GERD
- chest pain (like angina)
- nonallergic asthma
- chronic cough
- hoarsness
- pharyngitis
- dental erosions
-
alarm symptoms
- dysphagia - difficulty swallowing
- odynophagia - pain on swallowing
- unexplained weight loss
- GI bleeding
-
symptoms of GERD in infants
- irritability
- fussiness
- hiccups
- in ability to sleep
- frequent vomiting
- refusal to eat
- frequent cough and coughing fits
-
Which GERD symptoms require MD referral
- alarm symptoms
- atypical symptoms
- childrend <12 yo
- failure to respond to OTC therapy
-
clinical diagnosis of GERD
trouble symptoms more than or equal to 2 times/week
give empiric treatment, it symptoms get better, then diagnosis is made
-
further diagnostic evaluation of GERD symptoms is needed to make diagnosis if:
patient has alarm or atypical symptoms or they don't respond to therapy
- endoscopy (gold standard)
- PillCam Eso
- 24 hr Ambulatory pH monitoring
-
types of ambulatory pH monitoring
- pH probe
- radiotelemetry capsule
-
6 mechanism of therapeutic intervention
- increase LES pressure
- dec volume of gastric content available for reflux
- inc the pH of the refluxate
- enhance esophageal acid clearance
- improve gastric emptying
- protect esophageal mucosa
-
treatment for symptomatic relief of intermittent, mild heartburn
- lifestyle modification PLUS
- antacids AND/OR
- OTC doses of H2 blockers prn
-
treatment for symptomatic of relief of mild heartburn occurring more than 2 times/week
- lifestyle modification AND
- antacids OR
- OTC H2RAs OR
- OTC PPIs for 2 weeks
-
treatment for typical GERD symptoms
- lifestyle modifications PLUS
- standard Rx H2RAs for 6-12 weeks OR
- PPIs for 4-8 weeks
-
treatment for healing of erosive esophagitis or patients with complication or atypical symptoms
- lifestyle modifications PLUS
- PPIs for 4-16 weeks
can use high dose H2RAs for 8-12 weeks (but NOT RECOMMENDED)
-
Foods that dec LES tone
- chocolate
- peppermints
- alcohol
- fatty foods
-
drugs that promote reflux
- antichollinergics
- Beta blockers
- Ca channel blockers
- nitrates
- theophyline
-
direct irritant drugs
- tetracyclines
- KCl
- Fe
- ASA
- NSAIDs
- qunidine
- bisphosphonates
-
Antacid MOA
- neutralize existing acid -->
- dec conversion of pepsinogen to pepsin
- inc LES pressure
-
onset and duration of antacids
- onset: 5-15 min
- DOA: 1-3 hrs (give after meals to inc DOA)
-
Alginic Acid MOA
reacts with sodium bicarb and saliva to create a viscous solution that is refluxed before and in the place of gastric acid
-
Alginic acid compared to antacids
less neutralizing capacity or inc in LES pressure, but more effective than antacids alone
-
antacid dosing
dosed based on ANC (acid neutralizing capacity)
-
which antacid offers an adequate ANC w/ least potential for side effects?
AlOH
-
how should Gaviscon be given?
- in upright position
- not before bedtime
- thoroughly chew tablets
- followed by full glass of water
-
AEs of Mg products
- osmotic diarrhea
- accumulation/toxicity in renal disease
-
Mg toxicity
- depressed reflexes
- muscle paralysis
- hypotension
- bradicardia
-
AEs of Al products
- dose related constipation (can lead to obstruction)
- hypophosphatemia and bone demineralization (b/c binds to phosphate)
- accumulation/toxicity in renal disease
-
patients to avoid use of Al products in:
- dec bowel motility
- dehydration or fluid restriction
-
AEs of Mg-Al product combos
- diarrhea (but less than with Mg containing products)
- accumulation/toxicity in renal disease
- binding of phosphate - bone demineralization
-
AEs of CaCO3 containing products
- belching
- flatulence
- consitpation
- acid rebound (hypersecretion when the antacid leaves the stomach)
- hypercalcemia
- complications in renal disease
-
complication of CaCO3 in renal dieases
- confusion
- memory impairment
- kidney stones
- reduced renal function
-
AEs of Na bicarb products
- belching
- flatulence
- Na overload
- metabolic alkalosis (b/c of systemic absorption) in renal disease
- Milk-alkali syndrome
-
Milk-alkali syndrome
type of metabolic alkalosis caused by chronically ingesting Na bicarb with Ca
- vertigo
- irritability
- headache
- N/V
- weakness
- myalgias
- memory loss
- personality change
- coma
- renal failure
-
onset and DOA of H2RAs
can prevent heartburn if given 30-60 min b4 eating problematic foods
-
Standard doses of H2RAs
- given BID for 6-12 weeks
- not effective in erosive GERD
-
H2RAs MOA
competes with histamine for inhibition of the H2 receptors to decrease acid secretion from the parietal cells
- inc gastric pH
- dec activation of pepsinogen
- dec volume of gastric content available for reflux
-
H2RAs and renal functions
- lower OTC doses not affected by renal function
- standard doses need to be adjusted
-
pediatric H2RA dose
ranitidine 2 mg/kg BID
-
H2RA assoicated with the most AEs
cimetidine
-
AEs of H2RAs
generally well tolerated
-
H2RA drug interactions
basically all drugs that need acidic medium for absorption
-
OTC PPI indication
- heartburn that occurs more than 2 times/week
- take daily (not effective with prn use)
-
PPI MOA
- irreversible binding of H-K ATPase pump on parietal cells
- irreversible inhibition of final step of gastric acid release
-
what pumps do the PPIs inhibit? and when can complete relief be felt?
only the ones that are actively secreting
relief in 4 days
-
PPI dosing
- usually QD
- can be BID if QD doesn't work (b4 considering treatment failure)
mild heartburn: for 14 days (don't take for longer unless under MD supervision; don't self treat more than every 4 mos unless otherwise told by MD)
symptomatic GERD: for 4-8 weeks
healing of erosive esophagitis: for 4-12 wks
-
PPI dosing for pts with atypical symptoms
4 weeks of BID initially
-
Administration of PPI
- 30 min before first morning meal
- second dose is 30 min before evening meal
can also do BID for first 2-3 days of therapy; can also do H2RA combo for first 2-3 days of QD therapy
-
immediate release PPI
omeprazole (Zegerid)
-
dexlansoprazole
dual delayed release capsule with granules that can be sprinkled into things
-
PPI AEs
- Vitamin B12 malabsorption
- hip fractures (b/c of malabsorption of Ca
-
PPI drug interactions
- CYP 3A4 and CYP 2C19
- clopidogrel (pantoprazole has least interaction with this)
- monitor INR when taking with warfarin
- monitor phenytoin levels
- digoxin levels with rabeprazole
-
promotility agents in GERD
- bethanechol
- metoclopramide
- cisapride
-
Bethanechol MOA, AEs, DIs
- MOA: cholinergic stimulent, inc LES pressure and esophageal clearance
- AEs: ab cramps, diarrhea, blurred vision, inc urination
- DIs: other cholinergic and sympathomimetic agents
-
Metoclopramide MOA, AEs, DIs
- MOA: dopamine antagonist, inc LES pressure, accel gastric emptying
- AEs: extrapyramidal effects, restlessnes, drowsiness, gynecomastia
- DIs: CNS depressants (additive), other dopamine antagonists or drugs that case extrapyramidal effects
-
Cisapride MOA, AEs, DIs
- MOA: facilitates Ach release, inc LES pressure, accel gastric emptying
- AEs: cardiac arrhythmia, ab cramping, diarrhea
- DIs: life-threatening interaction with CYP 3A4 inhibitors, concurrent use with meds known to prolong QT interval
dose reduce in pts with renal or hepatic impairment
-
Nissen fundoplication
stomach fundus wrapped around distal esophagus
inc LES performance,
|
|